Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Pfizer Consumer relies on Alacer addition; Latin America strong for Bayer OTCs; Allegra Japan launch drives Sanofi OTC growth; Herbalife overcomes investor “noise”; Rx slide offsets Merck OTC gains.
You may also be interested in...
The Big Pharma disappoints investors with a weak first quarter and a failure to come to any decisions about the future structuring of the company. Meanwhile, the company made little progress of note during the quarter.
Bragg Live says its survey highlights misconceptions consumers have concerning health benefits and efficacy of different delivery formats of apple cider vinegar.
NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.